The global menopause treatment market is projected to grow from USD 799 million in 2025 to USD 1.38 billion by 2035, registering a compound annual growth rate (CAGR) of 5.6% over the forecast period. This growth is driven by increasing awareness about menopause-related health issues, rising geriatric female population, and expanding access to advanced hormone replacement therapies (HRT) and non-hormonal treatment options.
| Attributes | Details |
|---|---|
| Market Value for 2025 | USD 799 million |
| Market Value for 2035 | USD 1.38 billion |
| Market CAGR from 2025 to 2035 | 5.6% |
Menopause treatments address symptoms such as hot flashes, night sweats, mood swings, and osteoporosis, improving quality of life for millions of women worldwide. The market includes hormonal therapies, non-hormonal medications, herbal supplements, and emerging therapies like selective estrogen receptor modulators (SERMs) and tissue-selective estrogen complexes.
Growing patient preference for personalized and safer treatment options has encouraged pharmaceutical companies to innovate and diversify their product portfolios. Additionally, rising healthcare expenditure and supportive regulatory frameworks are boosting market accessibility, especially in developed regions like North America and Europe. Meanwhile, increasing awareness campaigns and healthcare infrastructure improvements in Asia Pacific are contributing to accelerated market growth.
In an interview with Reuters in March 2024, Lars Fruergaard Jørgensen, CEO of Novo Nordisk, stated, “I expect that over time we'll see a lower price point that will cater for more and more patients getting on treatment.” His remarks highlight the industry’s ongoing focus on innovation, accessibility, and patient-centric care across therapeutic areas.
With continued advancements in treatment options and growing global demand, the menopause treatment market is poised for steady growth through 2035.
Horizontal slicers are forecasted to dominate the industrial food slicers market with a 40% share in 2025, driven by their high efficiency and versatility in slicing a wide range of food products. The meat and poultry segment leads applications at 30%, fueled by growing demand in supermarkets and foodservice industries.
Horizontal food slicers are expected to hold the largest share, around 40%, in the industrial food slicers market by 2025. These slicers are widely used for precise and consistent slicing of meat, cheese, bread, fruits, and vegetables in commercial kitchens, food processing plants, and supermarkets. Their ability to handle large volumes with adjustable slice thickness makes them indispensable for high-throughput environments.
Innovations in blade technology, automated feeding mechanisms, and safety features have enhanced the operational efficiency and reliability of horizontal slicers. Brands like Marel, Bizerba, and Urschel continue to invest in energy-efficient and easy-to-clean slicer models that meet stringent food safety standards.
The increasing popularity of pre-packaged, sliced meat and deli products in retail and foodservice sectors further boosts demand for horizontal slicers. Their integration into modern food production lines ensures consistent product quality, waste reduction, and faster processing times, making them a market favorite worldwide.
The meat and poultry segment is projected to lead the industrial food slicers market with a 30% share in 2025, driven by rising global consumption of processed and ready-to-eat meat products. Growth in supermarkets, restaurants, and foodservice outlets is fueling demand for efficient slicing solutions to meet consumer expectations for quality and convenience.
Industrial food slicers improve slicing precision, uniformity, and speed, which are vital for portion control and enhancing product appearance. Increasing automation and mechanization in meat processing plants, driven by hygiene regulations and cost optimization, further propel market growth.
Emerging markets with expanding urban populations and rising disposable incomes are witnessing accelerated growth in meat and poultry slicing applications. Leading slicer manufacturers focus on developing versatile equipment that handles various meat textures and sizes while ensuring compliance with food safety regulations.
As consumer trends favor convenience foods and premium sliced meat products, the meat and poultry segment will remain a key growth driver in the industrial food slicers market through 2035.
To strengthen access of patients to menopause treatments the providers are conferring digital health and telemedicine platforms. The collaboration of telemedicine providers and menopause treatment providers results in the enhancement of patient awareness, support, and treatment process compliance.
Traditional hormone replacement therapy (HRT) got out of trend, with bioidentical hormone therapy (BHT) picking up steam. The menopause treatment providers benefit from this emerging trend by making BHT products and providing customized treatment alternatives tailored to individual requirements.
| Attributes | Details |
|---|---|
| Market Value for 2020 | USD 499.4 million |
| Market Value for 2024 | USD 758.5 million |
| Market CAGR from 2020 to 2024 | 7.80% |
The menopause treatment market is examined in the table below, which concentrate on the dominating regions in North America, Europe, and Asia Pacific. An extensive menopause treatment market analysis demonstrates that Europe has considerable market opportunities.
| Countries | CAGR (2025 to 2035) |
|---|---|
| Italy | 5.80% |
| Germany | 5.60% |
| France | 5.20% |
| Spain | 4.60% |
| United Kingdom | 4.40% |
Italy Industry Outlook
The Italy menopause treatment product market is ushered by a preference for natural treatments, traditional herbal remedies and substitute drugs play a significant role. Women in Italy look out for hormone therapy customized to their symptoms and health requirements during menopause, which thrives the menopause treatment market growth.
The public health programs of Italy strongly emphasize education and awareness efforts to de-stigmatize menopause and inspire women to seek healthcare on a regular basis.
Germany Industry Outlook
Menopause clinics and specialized healthcare centers are emerging in Germany, which indicates a surging demand for extensive care for menopausal women. The inclination toward digital health platforms and telemedicine services among German women provides handy access to necessary information and menopause-related consultations, bolsters the demand for menopause treatments.
France Industry Outlook
The menopausal clinics and other specialist healthcare services are set up due to the advancing awareness of menopause as a disorder that occurs with aging requiring specific treatment. To give patients comprehensive treatment choices, France’s healthcare providers are incorporating complementary therapies like acupuncture, yoga, and osteopathy into menopause management strategies. This trend indicates a surge in menopause treatments sales in France.
Spain Industry Outlook
Exhibiting a cultural transition for natural solutions to health, women in Spain move to traditional Mediterranean eating habits and integrate herbal medicines like red clover and sage to manage menopause symptoms. Menopause education and support campaigns are prevailing that cater to women the awareness and information required to face this life change, ushering the menopause treatment product market growth in Spain
United Kingdom Industry Outlook
Workplace policies are evolving into menopause-friendly and are prevalent in the United Kingdom, and these actions help to create a friendly and encouraging environment for women going through menopause. Smartphone applications and digital health platforms are pervasive in the United Kingdom.
These data sources support women with ease of access to self-management tools, menopausal education, and teleconsultations. In light of this trend the menopause wellness market is on the path to witness significant expansion.
| Countries | CAGR (2025 to 2035) |
|---|---|
| Canada | 4.10% |
| United States | 3.00% |
The booming expenses of healthcare and broadening healthcare infrastructure in the United States bolster the adoption of menopause treatments, mainly in rural areas. The soaring research and development activities in Canada concentrate on the innovation of non-hormonal therapies, which coincide with the choices of women looking for replacements that cause minimal side effects.
| Countries | CAGR (2025 to 2035) |
|---|---|
| China | 3.20% |
| South Korea | 2.40% |
| Japan | 1.60% |
China Industry Outlook
Traditional Chinese medicine is highly instrumental in managing menopausal symptoms and accelerating menopause treatment market growth. As customers seek natural remedies and herbal supplements, this flourishes the adoption of menopause treatments in China.
South Korea Industry Outlook
Society’s perception of menopause is changing, which has led to the escalated adoption of menopause treatments in South Korea. Better access to innovation in technology and healthcare infrastructure amplifies the menopause treatment market growth in South Korea.
Japan Industry Outlook
Reliable menopausal treatments are in demand in Japan due to the country's aging population and evolving population demographics. Women have an array of choices for controlling menopausal symptoms because of the coexistence of modern therapeutic approaches and traditional Japanese medicine, such as Kampo therapy. These factors intensify the adoption of menopause treatments in Japan.
Several menopause treatment providers dominate the competitive landscape, propelling developments and determining the market shift. Renowned pharmaceutical companies such as Eli Lilly and Company, Merck KGaA, Novartis AG, Bayers AG, and Pfizer, Inc. are at the vanguard. These menopause treatment providers' comprehensive expertise and resources make them essential for market growth.
The prominent menopause treatment vendors comprise Novo Nordisk, Ascend Therapeutics, Mylan N.V. [Viatris], Cipla, Inc., and Glenmark Pharmaceuticals Ltd., each bringing their diverse strengths and product portfolio. Emerging menopause treatment creators like MenoGeniX, Perrigo Pharma International D.A.C., Ausio Pharmaceuticals, LLC, EndoCeutics, Inc., and Radius Health, Inc. bring innovation and modernization to the competitive landscape.
These menopause treatment suppliers always fight to develop better treatment choices, address upcoming medical requirements, and enhance patient outcomes. The competition aids the market for advanced innovation, stimulates research and development, and ultimately benefits individuals looking for menopause treatments.
It can be inferred that as menopause treatment providers continue to tread through the menopause treatment market complexities, a foundation is laid for advancements and improvements resulting in treatment for better women's health.
Noteworthy Progressions
| Company | Details |
|---|---|
| Astellas Pharma Inc. | VEOZAH (fezolinetant) by Astellas Pharma Inc. received FDA approval, the first of its kind nonhormonal neurokinin 3 (NK3) receptor antagonist, in May 2023. VEOZAH is used to treat vasomotor symptoms (VMS) created due to menopause. |
| Amyris, Inc. | Amyris, Inc. bought MenoLabs, LLC in March 2022. MenoLabs, LLC treated women experiencing menopause and conducted research. Amyris, Inc. increased the range of menopausal treatment products it offers owing to the acquisition. |
| Pfizer Inc. | In May 2021, the United States Food and Drug Administration (FDA) authorized MYFEMBREE® to Myovant Sciences and Pfizer Inc. It was the first daily medicine for premenopausal women associated with the problem of excessive menstrual bleeding linked with uterine fibroids. |
| Bayer AG | Bayer AG announced in March 2020 that it acquired KaNDy Therapeutics, a prominent provider of women's healthcare goods, including menopause treatment products. The acquisition significantly strengthened its line of women's healthcare products. |
| Amgen | The FDA approved EVENITY (romosozumab-aqqg) in April 2019 by Amgen to treat postmenopausal osteoporosis. Women are prone to osteoporosis fractures more often than males, particularly after menopause. |
| Report Attributes | Details |
|---|---|
| Market Size (2025) | USD 799 million |
| Projected Market Size (2035) | USD 1.38 billion |
| CAGR (2025 to 2035) | 5.6% |
| Base Year for Estimation | 2024 |
| Historical Period | 2020 to 2024 |
| Projections Period | 2025 to 2035 |
| Quantitative Units | USD million for value and number of prescriptions/units for volume |
| Product Types Analyzed (Segment 1) | Hormone Therapy, Combination, Tibolone, Progestin-only Medicines, Estrogen-only Medicines, Non-Hormonal Therapy, Gabapentinoids, Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Selective Serotonin Reuptake Inhibitors (SSRI), Others |
| Routes of Administration Analyzed (Segment 2) | Topical, Injectable, Oral |
| Distribution Channels Analyzed (Segment 3) | Institutional Sales, Hospitals, Specialty Clinics, Retail Sales, Retail Pharmacies, Drug Stores, Supermarkets/Hypermarkets, Online Sales |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa |
| Countries Covered | United States, Canada, Brazil, Mexico, Germany, France, United Kingdom, Italy, Spain, China, Japan, South Korea, India, Australia, UAE, South Africa |
| Key Players Influencing the Market | Eli Lilly and Company, Merck KGaA, Novartis AG, Bayer AG, Pfizer, Inc., Novo Nordisk, Ascend Therapeutics, Mylan N.V. (Viatris), Cipla, Inc., Glenmark Pharmaceuticals Ltd., MenoGeniX, Perrigo Pharma International D.A.C., Ausio Pharmaceuticals, LLC, EndoCeutics, Inc., Radius Health, Inc. |
| Additional Attributes | Dollar sales, share trends, product demand by region, growth drivers, regulatory updates, consumer preferences, top-selling formulations, competitive landscape, pricing benchmarks, innovation opportunities, distribution channel shifts, emerging markets. |
The menopause wellness market to acquire a valuation of USD 799 million in 2025.
The menopause treatment product market has the potential to garner a worth of USD 1.38 billion by 2035.
The menopause wellness market equates to a moderate CAGR of 5.6% through 2035.
From 2020 to 2024, the menopause treatment product market evolved at a CAGR of 7.8%.
The oral sector is set to possess a market share of 58.8% in 2025.
The hormone therapy segment to garner a market share of 62.4% in 2025.
Explore Women's Health Insights
Menopause Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
